Super B and Lithium Werks sign strategic multi-year cell supply agreement to meet soaring demand for lithium batteries
HENGELO, The Netherlands, May 29, 2018 (GLOBE NEWSWIRE) -- Lithium battery specialist Super B (www.super-b.com) and cell supplier Lithium Werks B.V.(www.lithiumwerks.com) have signed a multi-year agreement that will secure worldwide supplies of lithium ion batteries to customers across the world.
Under the agreement, Lithium Werks, a fast-growing lithium battery and portable power solutions group, will gear up its continuous supply of high quality Lithium Werks Nanophosphate Tm Cells, as Super B continues to expand its operations in response to accelerating demand for lithium ion batteries.
"Leading companies in sectors such as automotive, industry, marine and renewable energy are already served by Super B, and their appetite for battery-powered solutions is only getting greater. We are looking forward to supporting Super B as they continue to serve this rapid growth in demand for lithium batteries," said T. Joseph Fisher III, CEO and co-founder of Lithium Werks.
"I have been impressed by Super B's ability to expand quickly in recent years and by its ambition to grow even faster in the years to come. We expect Super B to double in size every year for some time yet and I am happy to say that Lithium Werks has found a strong strategic partner in Super B," Mr Fisher said.
"We are pleased to be partnering with Super B in this long-term strategic alliance as their products and innovations are a perfect match with our proprietary patented Nanophosphate Tm cylindrical cells," Mr Fisher said.
Super B's CEO Henk Kleef said the agreement will benefit its customers.
"This long-term supply agreement for high quality cells from a truly global company like Lithium Werks will further bolster our ability to expand capacity and serve our customers' near insatiable demand for our lithium battery solutions in the coming years," Mr Kleef said.
"Lithium Werks, which has a strong reputation as a provider of Lithium Iron Phosphate cells, modules and scalable power systems, is an ideal partner as we continue to deliver long lasting, safe and reliable energy solutions to our customers," Mr Kleef said.
Both Super B and Lithium Werks specialise in Lithium Iron Phosphate technology, a lithium-ion chemistry that offers high thermal and chemical stability and is seen as the safest lithium-ion technology available today. The strategic cooperation builds on an existing relationship that has now become even stronger.
About Super B
Super B has a strong reputation for developing and producing unique high-end lithium batteries for a variety of industries and applications. Various leading manufacturers and customers in markets such as automotive, recreational vehicles, motorcycles, UPS and marine have experienced the innovative and reliable Super B lithium battery solutions. The Super B solutions are developed and produced in Hengelo, The Netherlands and supported with worldwide regional sales/service centers.
About Lithium Werks
Lithium Werks is a fast-growing global lithium ion battery company with production facilities in China and offices in the USA, the Netherlands, Northern Ireland, Great Britain and Norway. Lithium Werks provides cells, modules, and battery management systems into markets such as material handling, stationary energy storage, medical, and commercial marine.
Lithium Werks Press/Media Relations Telephone +44 (0) 28 9084 5411
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lithium Werks via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Cargotec files listing application in respect of its bonds in the aggregate amount of EUR 250 million18.9.2019 13:00:00 CEST | Press release
CARGOTEC CORPORATION, STOCK EXCHANGE RELEASE, 18 SEPTEMBER 2019 AT 2:00 PM (EEST) Cargotec files listing application in respect of its bonds in the aggregate amount of EUR 250 million NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Cargotec Plc decided on 13 September 2019 to issue two unsecured bonds in the total aggregate nominal amount of EUR 250 million. The first EUR 100 million bond matures on 23 January 2025 and carries a fixed annual interest of 1.250 per cent (ISIN: FI4000399688). The other, a EUR 150 million bond matures on 23 September 2026 and carries a fixed annual interest of 1.625 per cent (ISIN: FI4000399696). Cargotec Plc has today filed an application with Nasdaq Helsinki Ltd for the admission to trading of the bonds on the official list of Nasdaq Helsinki Ltd. Such application is subject to the F
New liquidity providing agreement for Aspo Plc’s share18.9.2019 12:00:00 CEST | Press release
ASPO Plc Stock exchange release September 18, 2019 at 13:00 New liquidity providing agreement for Aspo Plc’s share Aspo Plc and Lago Kapital Ltd have signed a market making agreement in compliance with the Liquidity Providing (LP) requirements issued by Nasdaq Helsinki Ltd. Concurrently, Aspo has terminated its current liquidity providing agreement with Nordea Bank. The current agreement will be in force until Friday October 18, 2019. The new liquidity providing agreement will commence on Monday 21 October, 2019. According to the agreement, Lago Kapital Ltd will provide Aspo’s share with bids and offers so that the maximum spread is 3 per cent, calculated from the bid quotation. Both bid and offer side shall include a number of shares corresponding to the value of at least 3,000 euros. The agreement is in force for a fixed period of 3 months and thereafter until terminated with one month’s term of notice. The market making agreement aims at increasing the share's liquidity and decreasi
Suominen’s financial reporting in 202018.9.2019 12:00:00 CEST | Press release
Suominen Corporation's stock exchange release on September 18, 2019 at 1:00 p.m. EEST Suominen will publish its Financial Statements Release, Half Year Financial Report and two Interim Reports in 2020 as follows: January 29, 2020 - Financial Statements Release for 2019 April 23, 2020 - Interim Report for January-March 2020 August 12, 2020 - Half Year Financial Report for January-June 2020 October 22, 2020 - Interim Report for January-September 2020 The Annual Report for 2019 will be published during the week starting on February 24, 2020 (week 9) at the latest. Suominen's Annual General Meeting is planned to be held on Thursday, March 19, 2020. Suominen's Board of Directors will summon the meeting at a later date. For more information: Emilia Peltola, VP, Communications and IR, tel. +358 10 214 3082 Suominen manufactures nonwovens as roll goods for wipes as well as for medical and hygiene products. The end products made of Suominen’s nonwovens – wet wipes, feminine care products and sw
Nomination Committee for SEB appointed18.9.2019 10:00:00 CEST | Press release
Press release Stockholm 18 September 2019 Nomination Committee for SEB appointed SEB’s Annual General Meeting will be held on Monday, 23 March 2020. The Nomination Committee members are: Petra Hedengran, Investor, Chairman Magnus Billing, Alecta Lars Heikensten, Trygg-Stiftelsen Johan Sidenmark, AMF Marcus Wallenberg, Chairman of the Board, SEB The shareholders having appointed members of the Nomination Committee together represent approximately 36,1 per cent of the voting rights for all shares in the Bank. The SEB Board has appointed Sven Nyman additional member of the Committee. The Nomination Committee will prepare a proposal for Directors etc. to be presented to the Annual General Meeting 2020 for decision. The matters to be dealt with by the Nomination Committee are described on www.sebgroup.com under the heading ‘Annual General Meeting’. A shareholder who would like to submit a proposal to the Nomination Committee can do so by e-mail to firstname.lastname@example.org or by ordinary
Valberedning för SEB utsedd18.9.2019 10:00:00 CEST | Pressemelding
Pressmeddelande Stockholm 18 september 2019 Valberedning för SEB utsedd Årsstämma för Skandinaviska Enskilda Banken kommer att hållas måndagen den 23 mars 2020. Valberedningen består av: Petra Hedengran, Investor, ordförande Magnus Billing, Alecta Lars Heikensten, Trygg-Stiftelsen Johan Sidenmark, AMF Marcus Wallenberg, styrelsens ordförande, SEB De aktieägare som utsett ledamöter till valberedningen, representerar tillsammans cirka 36,1 procent av röstetalet för samtliga aktier i banken. SEB:s styrelse har utsett Sven Nyman att vara adjungerad ledamot av valberedningen. Valberedningen har till uppgift att arbeta fram ett förslag till styrelse m.m. att läggas fram för beslut på årsstämman 2020. De frågor valberedningen ska behandla finns beskrivna på www.sebgroup.com/sv under rubriken ”Årsstämma”. Aktieägare som önskar lämna förslag till valberedningen kan göra det med e-post till email@example.com eller med brev till Skandinaviska Enskilda Banken AB, Valberedningen, Att: Ulf Thornan
MiniMed™ 670G System European Real-World Data Shows 73% Time in Range, Beyond Recommended Targets18.9.2019 09:00:00 CEST | Press release
DUBLIN, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions today announced real-world clinical outcomes on European patients for the MiniMed™ 670G system. The European data showed an average Time in Range of 73%1, a result that exceeds the recommended Time in Range consensus guidelines of 70% that were recently published2. The real-world data of 4,369 patients showed an average estimated HbA1c of 6.9%*1, also surpasses the recommended target.3 The SmartGuard™ Auto Mode feature in the MiniMed 670G system automates and personalizes the delivery of basal insulin 24 hours a day. This system is the only commercially available technology in the world to provide protection from highs and lows, and proactively drive increased Time in Range by consistently guiding to the target of 120 mg/dL (6.7mmol/L) throughout the day.4,5 “The Time in Range clinical guidelines recommend that the target of effective diabetes management